NewsBenzingaLantheus Holdings Announces First Patient Dosed In SPARROW NCT07831824, Phase 2/3 Registrational Trial Evaluating LNTH-2401 Lantheus Holdings Announces First Patient Dosed In SPARROW NCT07831824, Phase 2/3 Registrational Trial Evaluating LNTH-2401 Benzinga 2026.09.28 12:04 (GMT+0) Open on Benzinga Other news Public companies net bought $360M in Bitcoin last week, Strive contributed over 90% Stocks Supported by a Rebound in Chipmakers and AI-Infrastructure Companies Taiwan’s President Called on Micron and Workers to Negotiate Ahead of a Possible Strike. Here’s What to Know. US memory chip stocks rally broadly, several gain over 5% 3 Token Unlocks to Watch in the Fourth Week of October 2026 Arbitrum Community Proposes Adding USDG to Core Strategic Plan with Additional 100M ARB Incentives
Taiwan’s President Called on Micron and Workers to Negotiate Ahead of a Possible Strike. Here’s What to Know.
